Cambridge Investment Research Advisors
ELEV

Cambridge Investment Research Advisors’s Elevation Oncology ELEV Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,242
Closed -$83K – 3354
2024
Q1 		$83K Buy
+16,242
New +$52.6K ﹤0.01% 3167

Other funds holding ELEV

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Cambridge Investment Research Advisors's ELEV Position: Q2 2024 in Review

Cambridge Investment Research Advisors sold out of Elevation Oncology (ELEV) in Q2 2024, closing a stake of 16,242 shares — an estimated $83K sold.

Cambridge Investment Research Advisors first reported a position in ELEV in Q1 2024 and held it in 1 quarter. The position peaked at $83K in Q1 2024. 81 funds tracked by Wall St. Rank hold ELEV as of Q2 2024.

  • Cambridge Investment Research Advisors reported no remaining Elevation Oncology position as of Q2 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 16,242 Elevation Oncology shares in Q2 2024, an estimated $83K.
  • Cambridge Investment Research Advisors first reported a position in Elevation Oncology in Q1 2024 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Elevation Oncology position peaked at $83K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.